Relmada Therapeutics
RLMD
48 hedge funds and large institutions have $4.36M invested in Relmada Therapeutics in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 20 reducing their positions, and 28 closing their positions.
160% more call options, than puts
Call options by funds: $340K | Put options by funds: $131K
13.18% less ownership
Funds ownership: 41.02% → 27.84% (-13%)
30% less funds holding
Funds holding: 69 → 48 (-21)
45% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 20
75% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 28
89% less capital invested
Capital invested by funds: $40.2M → $4.36M (-$35.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$366K |
| 2 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$345K |
| 3 |
Renaissance Technologies
New York
|
+$338K |
| 4 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
+$244K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$216K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$2.19M |
| 2 |
PCM
Parsons Capital Management
Providence,
Rhode Island
|
-$2.05M |
| 3 |
Millennium Management
New York
|
-$1.82M |
| 4 |
VPC
Vestal Point Capital
New York
|
-$1.59M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.56M |
RLMD Hedge Fund Activity: Q4 2024 in Review
48 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q4 2024, worth a combined $4.36M — down 89% from $40.2M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of RLMD and 7 opened new positions — a net loss of 21 holders — while 20 trimmed existing stakes and 11 added.
The largest buyer was Tang Capital Management, adding an estimated $366K. The largest seller was Deep Track Capital, exiting entirely with an estimated $2.19M sold.
- 48 institutional investors held Relmada Therapeutics (RLMD) as of Q4 2024, down from 69 in Q3 2024.
- Funds reported $4.36M of Relmada Therapeutics stock for Q4 2024, down 89% quarter-over-quarter.
- 7 funds opened new Relmada Therapeutics positions in Q4 2024 and 28 closed out, a net change of -21 holders.
- The largest Relmada Therapeutics buyer in Q4 2024 was Tang Capital Management, an estimated $366K added.
- The largest Relmada Therapeutics seller in Q4 2024 was Deep Track Capital, an estimated $2.19M sold.
Based on aggregated 13F filings for Q4 2024.